tbuckley/cabot-search huggingface dataset:
Incidence and characterization of pure non-urothelial bladder and upper tract cancers: A 10-year review.
Authors: Kanika Gupta, Ehab El Bahesh, Antoine Nafez Finianos, Brandon Clark, Samuel Simmens, Jeanny B. Aragon-Ching
Journal: Journal of Clinical Oncology (2016)

414 Background: Bladder cancer is the sixth most common malignancy in the United States. Urothelial carcinoma makes up 90% of bladder cancer histology, which may be pure or mixed. It includes adenocarcinoma (Ad), squamous (SqC), glandular, sarcomatoid (St), micropapillary, small cell (SC) and plasmacytoid variants. Pure non-urothelial cancers have worse overall survival compared to urothelial cancer with mixed histologic features. However, little research has been done to characterize pure non-urothelial histologies, and there are no randomized clinical trials evaluating treatment modalities for non-urothelial cancers. This retrospective study characterizes pure non-urothelial cancers and their treatments. Methods: A retrospective chart review of the last 10 years was performed using data from the George Washington University Cancer Center Tumor Registry Data. Statistical analysis was done using the Fisher’s test and Kaplan-Meier survival curves. Results: Out of 449 consecutive patients with bladder cancers, 19 patients had pure non-urothelial carcinoma (4.2%): 7 SqC, 6 Ad, 3 SC, 2 lymphoma (Ly), and 1 St. SqC and Ad were more likely than SC to be diagnosed at an advanced stage (p = 0.04), with median age of diagnosis at 53.5 years for Ad, 68 years for SC and 69 years for Sq. None of the SC metastasized. Primary treatment for 94% of patients was a surgical intervention (9 TURBT, 2 partial cystectomy, 2 radical cystectomy, and 2 nephroureterectomy); 1 received neoadjuvant therapy. 11 patients received adjuvant chemotherapy – 7 with gemcitabine-based regimens and 10 with platinum-based regimens. While not statistically significant, median overall survival varied – 404 days for Ad, 213 days for SqC, and 1567 days for SC. Conclusions: SC was a more favorable histology when compared to SqC or Ad, presenting at an earlier stage with lower incidence of metastasis that perhaps reflected the improved overall survival. Identifying patients with more aggressive disease earlier allows for the potential role for more aggressive therapies that may result in improved outcomes. While the sample size is small, it identifies characteristics and potential differences between bladder cancer with rare histologies.
Phase II studies of AZD1775, a WEE1 kinase inhibitor, and chemotherapy in non-small-cell lung cancer (NSCLC): Lead-in cohort results
Authors: D.R. Spigel, S. Dakhil, J.T. Beck, A. Sadiq, S. Menon, C.D. Webb, F.Y. Tsai, M. Johnson, S.F. Jones, C. Greenlees, D.M. Stults, D. Strickland, C. Cook, G.M. Mugundu, N.M. Laing, T. French, H.A. Burris
Journal: Annals of Oncology (2016)
Quality oversight for specialized cancer services.
Authors: Sherrie Hertz, Jillian Ross, Leonard Kaizer, Carol Anne Sawka
Journal: Journal of Clinical Oncology (2012)

103 Background: Cancer Care Ontario (CCO), a provincial agency responsible for continually improving cancer services in Ontario, Canada, reviews selected services with a view to understanding and resolving issues of access, quality, innovation, and funding. Specialized cancer services are low-volume, high-complexity, high-cost, and are not available in every region. They tend to be high-risk, involve a rapidly evolving scientific knowledge base, and a high degree of specialization. A specialized services oversight (SSO) approach has been implemented to address the challenge for optimization of service delivery while providing equitable access to safe, high-quality, best practice care. Methods: The SSO approach involves 1) establishing a provincial forum for expert clinical advice; 2) A regular and systematic process for literature and jurisdictional reviews; 3) provincial-level demand and capacity forecasting; 4) provincial funding linked to evidenced-based eligibility/quality criteria; 5) communication/awareness strategies for appropriate and equitable access. Enablers are CCO structures for performance management, stakeholder engagement, service planning, data management, and CCO’s guiding principles of "transparency, equity, evidence, performance-oriented, active engagement, and value for money." Results: The SSO approach has been implemented in full for PET scanning services, and in part for stem cell transplant (SCT), sarcoma, molecular oncology, prostate brachytherapy, and selected neuroendocrine cancer care. Stakeholder acceptance of the approach has been high. Outputs include provincial guidelines on indications for SCT, performance metrics and benchmarks, multicentre sharing of information, and inter-regional referral processes. Conclusions: Implementation of the SSO approach has introduced provincial-level system planning, formal evidence scanning, sharing of best practices, and performance measurement for high-complexity services where there was no such oversight in the past. The approach is anticipated to avoid access crises and support timely and equitable access to services of high quality, which make optimal use of resources.
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer
Authors: A. Sabharwal, P. Corrie, A. Seebaran, D. Anderson, J. Carmichael, P. Mortimer, G. P. Margison, A. Watson, M. R. Middleton
Journal: Journal of Clinical Oncology (2007)

2535 Background: The DNA repair protein O 6 -methylguanine DNA methyltransferase (MGMT) contributes to cellular resistance to irinotecan (IR) and its metabolite SN-38. In human cancer cell lines MGMT expression correlates with SN-38 sensitivity, inactivation of MGMT enhances cell killing and increasing MGMT expression by transfection increases resistance to IR. This study evaluated the safety, tolerability and pharmacokinetics (PK) and pharmacodynamic (PD) effects of lomeguatrib (LM), an MGMT inactivator, in combination with IR. Methods: Patients with stage 4 colorectal cancer, performance status 0–2 and adequate bone marrow and biochemical function took part in the trial, which followed a standard 3 patient cohort dose escalation design. LM was given daily PO for 5 days, with IR by IVI on day 4 of each 21 day cycle. Starting doses were 10 mg/day LM and 350 mg/m 2 IR. Tumor response to treatment was measured by RECIST criteria. Blood was taken for PK &amp; PD measurements in cycle 1. Results: 24 patients (14M/10F; median age 62) were enrolled. The first dose level was not tolerated, with 2 of 3 patients experiencing dose limiting haematological toxicity. The IR dose was decreased to 250 mg/m 2 for subsequent cohorts, and the LM dose escalated from 10 to 80 mg/day. With LM 80 mg/day a final 6 patient cohort received 300 mg/m 2 IR, establishing this as the maximum tolerated dose. Non-hematological toxicity matched that of single agent IR. No partial responses have been seen amongst 22 evaluable patients. 10 patients had prolonged disease stabilisation, completing all 6 treatment cycles, with another 3 patients still on treatment. There was no PK interaction between the drugs. Conclusion: LM and IR is well tolerated, requiring a modest reduction in the single agent dose of IR. Clinical activity, in this pre-treated population, is modest. PD data on MGMT levels and DNA-topoisomerase 1 complex formation in peripheral blood mononuclear cells, measured by bioassay and RIA respectively, will be presented. No significant financial relationships to disclose.
Fourteen Percent of Healthy African Americans Participating In the Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB VWD) Are Heterozygous for the VWF Gene Mutation H817Q Associated with Type 2N Von Willebrand Disease
Authors: Kenneth D Friedman, Daniel B. Bellissimo, Pamela A. Christopherson, Veronica H Flood, Joan Cox Gill, Robert R. Montgomery, Sandra L Haberichter, Primary Clinical Center Directors
Journal: Blood (2010)
Antigen Absorption is Correlated With Allergic Reaction Severity Upon Oral Peanut Challenge in Mice
Authors: Kelly Orgel, Michael D. Kulis, Martin T. Ferris, Ping Ye, Rishu Guo, Darla R. Miller, Fernando Pardo-Manuel de Villena, A. Wesley Burks
Journal: Journal of Allergy and Clinical Immunology (2017)
Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,
Authors: Richard A. Larson, Udomsak Bunworasate, Anna G. Turkina, Stuart L. Goldberg, Pedro Dorlhiac-Llacer, Jose L. Lopez, Hagop M. Kantarjian, Giuseppe Saglio, Andreas Hochhaus, Albert Hoenekopp, Rick E. Blakesley, Richard Yu, Neil J. Gallagher, Richard E. Clark, Timothy P. Hughes
Journal: Blood (2011)
Hepatocellular cancer tumor growth and metabolic risk factors.
Authors: Rebecca A. Miksad, Rohit Goyal, Jesse Wei, Raja Shaikh, Elkan F. Halpern, G. Scott Gazelle
Journal: Journal of Clinical Oncology (2013)

162 Background: Understanding hepatocellular cancer (HCC) tumor growth patterns is important for determining optimal treatment strategy. However, growth of untreated HCC tumors is unclear and prior studies are limited by older imaging technologies and small samples. We evaluated HCC growth patterns and predictors in a cohort of patients with serial modern computed tomography (CT) and magnetic resonance imaging (MRI). Methods: Two radiologists retrospectively evaluated CT and MRI imaging for 56 patients with 83 HCC tumors with at least two images. Tumor Volume (TV) = 4/3* π *average short axis (X)*average long axis (Y)*X. To assess the relative change in size, normalized tumor volume (NTV) = TV/ baseline TV. Growth curves were fitted using an exponential growth model for tumor &gt;2 observations. Univariate analysis explored clinical and pathologic predictors of NTV. A multivariate model was built by backward elimination of significant univariate variables. Results: Among 56 patients: 77% male, 96% cirrhotic, 50% Child-Pugh Class (CPC) B, 59% Hepatitis C, 32% obese, 37% diabetic, and 12% used metformin. Mean baseline and end TV were 98.8 cm 3 and 213.0 cm 3 , respectively. Mean follow-up=8.3 months and mean number of serial images=3. Exponential TV growth was observed on visual inspection. Diabetes predicted lower NTV (i.e. slower TV growth) in univariate and multivariate analysis (Table). Obesity decreased the impact of diabetes. Conclusions: Diabetic patients had slower growing tumors than non-diabetics, even when clinical and pathologic factors were controlled. Tumor growth fit an exponential pattern. Further study of the impact of metabolic conditions on HCC tumor growth may provide insights into growth factors and identify potential treatment targets. [Table: see text]
Nasal Responses and Safety of L-ASA Nasal Provocation Test in a Large Series of Patients with NSAID-Exacerbated Respiratory Disease (NERD)
Authors: Paloma Campo, Inmaculada DoÑa, Jesus Verge, Tahia D. Fernandez, Maria Dolores Cañamero, Jose Antonio Cornejo, Cristobalina Mayorga, Carmen Rondon Segovia, Maria J. Torres
Journal: Journal of Allergy and Clinical Immunology (2017)
Efficacy and Safety of Long-Term Epicutaneous Immunotherapy (EPIT) Treatment of Peanut Allergy with Viaskin® peanut: Results of the Two-Year Extension of the Vipes Phase IIb Clinical Trial
Authors: Wayne G. Shreffler, Kari C. Nadeau, Stephanie A. Leonard, Gordon L. Sussman, Hugh A. Sampson
Journal: Journal of Allergy and Clinical Immunology (2017)
Stromal Cell Line Enhances Survival of Myeloid Leukemia Cells by Regulating the Expression of bcl-2 Family Genes and Caspase-3.
Authors: Zhenshu Xu, Yongjun Liu, Zhibo Han, Lulu Lv, Ting Yang, Rui He, Zhizhe Chen, Zhongchao Han
Journal: Blood (2006)
Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM).
Authors: Rachid Baz, Mohamad Hussein, Daniel J. Lebovic, Elizabeth Finley-Oliver, Mehul P Patel, Hong Liu, Kena C Miller, Margaret Wood, Kelvin P. Lee, Asher Chanan-Khan
Journal: Blood (2009)
Development of a pCCLChim Lentiviral Vector for Gene Therapy of Patients with Chronic Granulomatous Disease (CGD) due to p47-phox Deficiency
Authors: Walmir Cutrim Aragao-Filho, Andrea Shejtman, Marta Zinicola, Ulrich Siler, Janine Reichenbach, H.B. Gaspar, Adrian Thrasher, Giorgia Santilli, Antonio Condino-Neto
Journal: Journal of Allergy and Clinical Immunology (2017)
The Exposure to Ambient Ozone Affects Clinical Symptom in Asthmatic Adults
Authors: Min-Young Jung, Young-min Kim, Jihyun Kim, Inbo Oh, Byung-Jae Lee, Dong-Chull Choi, Byoung-Hak Jeon, Hae-Kwan Cheong, Kangmo Ahn
Journal: Journal of Allergy and Clinical Immunology (2017)
Increased Expression of TIPE2 in Alternatively Activated Macrophages Is Associated with Chronic Rhinosinusitis with Nasal Polyps
Authors: Yin Yao, Zhi-Chao Wang, Jin-Xin Liu, Jin Ma, Cai-Ling Chen, Yi-Ke Deng, Bo Liao, Nan Wang, Yang Liu, Zheng Liu
Journal: Journal of Allergy and Clinical Immunology (2017)
Risk and Benefit Information and Use of Aspirin
Authors: JoAnn Sperl-Hillen, Karen Margolis, Lauren Crain
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Analysis of blood from Zika virus-infected fetuses: a prospective case series
Authors: Bruno Schaub, Manon Vouga, Fatiha Najioullah, Michèle Gueneret, Alice Monthieux, Caroline Harte, Françoise Muller, Eugénie Jolivet, Clara Adenet, Sophie Dreux, Isabelle Leparc-Goffart, Raymond Cesaire, Jean-Luc Volumenie, David Baud
Journal: The Lancet Infectious Diseases (2017)
The home self-monitoring of symptoms after chemotherapy in cancer patients with the use of ESAS scale
Authors: G. Cremona, S. Vescovi, L. Muroni, M. Cordani, M. Muroni, M. Marenghi, F. Trecordi, M. Marchionni, A. Lis, E. Casaroli, N. Bacchetta, T. Pochintesta, C. Paradiso, G. Claudia, E. Forelli, V. Tramelli, I. Vasiliu, M. Proietto, C. Biasini, P. Mordenti, L. Cavanna
Journal: Annals of Oncology (2016)
Mutually Exclusive Structural Alterations of BLIMP1 and BCL6 Contribute to the Pathogenesis of Activated B Cell Type Diffuse Large B Cell Lymphoma.
Authors: Jonathan Mandelbaum, Govind Bhagat, Adina Grunn, Manisha Brahmachary, Amy Chadburn, Riccardo Dalla-Favera, Laura Pasqualucci
Journal: Blood (2009)
Third Generation Chimeric Antigen Receptors Containing CD137 or CD134 Signaling Endodomains Augment CD19-Specific T-Cell Effector Function.
Authors: Harjeet Singh, Hillary N Gibbons, Simon Olivares, Matthew J. Figliola, Margaret J. Dawson, Mary Helen Huls, Dean A Lee, Partow Kebriaei, Richard E Champlin, Laurence J.N. Cooper
Journal: Blood (2009)
Genetic variations in the VEGF pathway as prognostic factors in stages II and III colon cancer
Authors: A.C. Virgili Manrique, P. Riera Armengol, J. Salazar Blanco, M. Tobeña, A. Sebio Garcia, M. Martín. Richard, E. del Rio Conde, N. Dueñas Cid, A. Vethencourt Casado, A. Barba Joaquín, M. Andrés Granyo, D. Paez
Journal: Annals of Oncology (2016)
Tumors of the Pleura Induced With Asbestos and Fibrous Glass: Reply
Authors: Mearl F. Stanton
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Tumors of the Pleura Induced With Asbestos and Fibrous Glass: Reply Get access Mearl F. Stanton Mearl F. Stanton Laboratory of Pathology National Cancer Institute, Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 1, July 1973, Pages 317–320, https://doi.org/10.1093/jnci/51.1.317 Published: 01 July 1973
TMOD-29. GLIOBLASTOMA PATIENT-DERIVED XENOGRAFT MICROTUMORS AS A HIGH THROUGHPUT PRECLINICAL TESTING PLATFORM
Authors: Christopher Willey, Yancey Gillespie, Joshua Anderson, Catherine Langford, Ashley Gilbert, Patricia Hicks, Rachael Shevin, Raj Singh
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) preclinical model systems for high throughput testing are limited by unnatural culture conditions (e.g. grown in serum) and expense (such as Patient-Derived Xenografts or PDX). While PDX can be grown in culture as neurospheres, these culture conditions do not provide key tumor microenvironment components seen in vivo. As such, there is a need for better model systems to test chemotherapy, small molecule inhibitors (SMI), and radiation. Utilizing a human-derived stromal matrix (HuBiogel, Vivo Biosciences, Birmingham, AL), we can grow GBM PDX as microtumors allowing for therapeutic testing (including combinations) in 96 and 384-well formats. Moreover, molecular “omic” testing can be performed to build companion biomarkers. GBM PDX were serially propagated in athymic nude mice through the UAB Brain Tumor Animal Models Core. PDX tumors were harvested and isolated as single cell suspensions for subsequent embedding into HuBiogel to form 3D microtumors at defined cell concentrations. These microtumors were maintained for up to 28 days, with phenotypic assays and molecular testing performed at 7-14 days. Therapies, including temozolomide, cediranib, WP1066, selumetinib, crizotinib, and radiation were tested alone or in combination. Immunohistochemistry (IHC), CellTiter-Glo, Calcein AM staining, and kinomic profiling in the UAB Kinome Core (kinomecore.com) using the PamStation®12 (PamGene, The Netherlands) were performed. We selected 7 GBM tumors from a well-characterized panel of 27 human GBM-PDX that represent the molecular subtype spectrum of disease seen in The Cancer Genome Atlas and reproduce histopathological hallmarks of GBM when grown orthotopically in mice. IHC examination of GBM PDX microtumors revealed multicellular organization replicating the in vivo tumor microenvironment. Molecular testing showed kinomic diversity in microtumors as well as differential sensitivity to chemotherapy, SMI combinations, and radiation (in combination with SMI). GBM PDX microtumors are well suited to high throughput therapeutic testing.
The Effects of Induction Chemotherapy and High-Dose Melphalan with Tandem Autologous Transplantation in Multiple Myeloma: The Prospective Randomized DSMM 2 Study.
Authors: Christian Straka, Peter Liebisch, Burkhard Hennemann, Bernd Metzner, Hans Salwender, Lothar Kanz, Sigrid Adler-Reichel, Wolf-Dieter Ludwig, Hannes Wandt, Martin Bentz, Tim Bruemmendorf, Markus Hentrich, Lorenz Truemper, Mathias Freund, Hans-Heinrich Wolf, Sezer Orhan, Ralf Bargou, Gottfried Doelken, Norbert Schmitz, Helga Bernhard, Martin Gramatzki, Norbert Frickhofen, Helmut Ostermann, Ralf Schmidmaier, Stefan Ibach, Axel Hinke, Hermann Einsele, Bertold Emmerich
Journal: Blood (2007)
Microrna-29b Targets PSME4 to Inhibit Proteasome Activity and Prevent the Delivery of Aggresomes to Autophagosomes for Anti-Myeloma Benefit
Authors: Sajjeev Jagannathan, Nikhil Vad, Mohamed A.Y. Abdel Malek, Ehsan Malek, James J. Driscoll
Journal: Blood (2014)
Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity
Authors: Daniel Primo, Joan Ballesteros, Antonio Jimenez, Ataulfo Gonzalez, Miguel Hernandez, Raul Cordoba, Yolanda González, Hernan Jose Moreno, Alicia Bailen, Jesus Martin, Anabelle Chinea, Asuncion Etxeveste, Jose Mariano Hernandez, Albert Oriol, Jaime Perez de Oteiza, Luis Palomera, Cristina Encinas, Felipe Prosper, Rebeca Iglesias, Laura Rosiñol, Alicia Robles, Julian Gorrochategui, Veronica Garcia, Pilar Hernandez, Enrique Ocio, Joaquin Martinez
Journal: Blood (2014)
Undocumented Immigrants and Access to Health Care
Authors: Alicia Fernández, Rudolph A. Rodriguez
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
SURG-16. MAGNETIC RESONANCE-GUIDED LASER ABLATION FOR THE TREATMENT OF RECURRENT DURAL BASED TUMORS
Authors: Michael E. Ivan, Roberto Jose Diaz, Michael Berger, David Osiason, Thomas Plate, Amanda Wallo, Ricardo J. Komotar
Journal: Neuro-Oncology (2016)

Magnetic resonance-guided laser-induced thermotherapy (MR-LITT) is a minimally invasive technique that shows promise in neuro-oncology due to its superiority in delivering precise minimally invasive thermal energy with minimal collateral damage. In this analysis we investigate initial data on MR-LITT’s effect on dural based lesions. Five patients were identified with dural based lesions (4 meningiomas, 1 solitary fibrous tumor) with clear evidence of radiological progression. All patients received MR-LITT and then a follow-up MRI scan at 24 hours post treatment, at one month, and at each subsequent follow up visit. Local control of the ablated tumor was evaluated with radiographic follow up and symptomatic progression free survival was recorded. Five LITT treatments were performed on 5 patients with the average age of 65.2 years. The average tumor volume was 29.7 cm3 and ablation dosage was 12.4 Watts. On average, 80% of the pretreatment lesion volume was ablated. The mean follow-up time was 59.3 weeks. In total, 2 patients (one with an anaplastic meningioma and one with a solitary fibrous tumor) had radiographic evidence of disease progression. In the observed time of the 3 patients with no progression there was a 52% reduction in tumor volume. There were no major perioperative complications. MR-LITT is a promising technology for dural based tumor treatment. This initial study demonstrates that MR-LITT is safe and offers several advantages over open surgical treatment. Randomized studies are needed to evaluate its role as a treatment adjunct.
Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.
Authors: Philipp D. le Coutre, Bernadeta Ceglarek, Anna Turkina, Dong-Wook Kim, Giuliana Alimena, Haifa Kathrin Al-Ali, Zhixiang Shen, Saengsuree Jootar, Graeme Smith, Carmino Antonio De Souza, David A Rizzieri, Tomasz Szczudlo, Myriam Berton, Jim Wang, Ellison Dial, Franck Emmanuel Nicolini
Journal: Blood (2009)